Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 10/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 8/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 4/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.45 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.45 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.45 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6996569 | 0.83 | GRIN2B (0.52) | GRIN2BGRIN1GRIN2DGRIN3BGRIN2A | |
| SCHEMBL6992524 | 0.76 | GRIN1 (0.57) | GRIN2BGRIN1GRIN2DGRIN3BGRIN2A | |
| SCHEMBL8114274 | 0.76 | GRIN2B (0.60) | GRIN2BGRIN1GRIN2DGRIN3BGRIN2A | |
| SCHEMBL7228618 | 0.74 | GRIN2B (0.61) | GRIN2BGRIN1GRIN2DGRIN3BGRIN2A | |
| SCHEMBL4674828 | 0.73 | GRIN2B (0.63) | GRIN2BGRIN1GRIN2DGRIN3BGRIN2A | |
| SCHEMBL4674832 | 0.73 | GRIN2B (0.63) | GRIN2BGRIN1GRIN2DGRIN3BGRIN2A | |
| SCHEMBL6996260 | 0.72 | GRIN1 (0.57) | GRIN2BGRIN1GRIN2DGRIN3BGRIN2A | |
| SCHEMBL7529124 | 0.72 | GRIN2B (0.70) | GRIN2BGRIN1GRIN2DGRIN3BGRIN2A | |
| SCHEMBL7037165 | 0.70 | GRIN1 (0.54) | GRIN1 | |
| SCHEMBL6998090 | 0.68 | GRIN2B (0.57) | GRIN2BGRIN1GRIN2DGRIN3BGRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6642256-B2 | Brain disorders, psychological disorders, antiischemic agents, central nervous system disorders | WARNER-LAMBERT COMPANY LLC | 2003-11-04 | — | — | US | claimed |
| EP-1345935-A2 | PIPERIDINE DERIVATIVES AS SUBTYPE SELECTIVE N-METHYL-D-ASPARTATE ANTAGONISTS | Warner-Lambert Company LLC (US) | 2003-09-24 | — | — | EP | claimed |
| US-20030018021-A1 | Piperidine derivatives as subtype selective N-methyl-D-aspartate antagonists | KORNBERG BRIAN EDWARD (US) | 2003-01-23 | — | — | US | claimed |
| WO-2002050070-A2 | PIPERIDINE DERIVATIVES AS SUBTYPE SELECTIVE N-METHYL-D-ASPARTATE ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-06-27 | — | — | WO | claimed |
| US-6642256-B2 | Brain disorders, psychological disorders, antiischemic agents, central nervous system disorders | WARNER-LAMBERT COMPANY LLC | 2003-11-04 | — | — | US | disclosed |
| EP-1345935-A2 | PIPERIDINE DERIVATIVES AS SUBTYPE SELECTIVE N-METHYL-D-ASPARTATE ANTAGONISTS | Warner-Lambert Company LLC (US) | 2003-09-24 | — | — | EP | disclosed |
| US-20030018021-A1 | Piperidine derivatives as subtype selective N-methyl-D-aspartate antagonists | KORNBERG BRIAN EDWARD (US) | 2003-01-23 | — | — | US | disclosed |
| WO-2002050070-A2 | PIPERIDINE DERIVATIVES AS SUBTYPE SELECTIVE N-METHYL-D-ASPARTATE ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018021-A1 | Piperidine derivatives as subtype selective N-methyl-D-aspartate antagonists | GRIN1, OPRD1, OPRM1 | GRIN2B 5/4885GRIN1 1/4885GRIN2D 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.